News

Replagal is an enzyme replacement therapy for the treatment of Fabry disease. With this approval, the company now has two approved facilities, Alewife, and the new Lexington facility,

The company has already received orphan drug designation from the European Medicines Agency for Graspa as a treatment for pancreatic cancer. Erytech Pharma co-founder, vice president and chief

Prior to that Hinchen was the president and chief operating officer of JHP since the formation of the company in 2007. Hinchen said JHP has a wonderful opportunity

Adcetris MAA was filed as a treatment for relapsed or refractory Hodgkin lymphoma (HL) and relapsed or refractory systemic anaplastic large cell lymphoma (sALCL) by Takeda Global Research

Intivia as an EHR Vendor, will offer small practices drive EMR adoption and leverage the benefits of InSync EMR & Practice Management software. NJ-HITEC executive director Bill Byrne

Further, both the companies have also decided to expand the term of their drug discovery and research agreement to April 2012. The companies aim to generate new chemical

The open-label study results demonstrated that Lantus and Apidra helped in lowering blood glucose levels in the study as compared to premixed insulin with less hypoglycemia and also

The payment was made in connection with Boehringer‘s decision for executing the development of lead Nanobody candidate targeting Alzheimer’s disease. Earlier, the research and licensing pact was signed

Votubia tablets are indicated as a treatment for children and adults suffering from subependymal giant cell astrocytoma (SEGA) or brain tumors linked with tuberous sclerosis complex (TSC). The